Skip to main content

GMCI Plus Standard of Care Immune Checkpoint Inhibitor for Stage III / IV NSCLC

Trial Status: Active

The purpose of this phase 2 multi-site trial is to evaluate the safety and efficacy of adding Gene Mediated Cytotoxic Immunotherapy (GMCI™) to standard of care in patients with stage III / IV NSCLC that are not responding to a first line immune checkpoint inhibitor (ICI). GMCI kills tumor cells and creates an immune stimulatory environment in the tumor. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. Patients will receive two courses of GMCI with aglatimagene besadenovec injected into an accessible involved tumor site followed by 14 days of oral valacyclovir. Patients will continue with standard of care ICI, plus chemotherapy if indicated. The hypothesis is that the combination of GMCI and ICI may improve the response rate and overall clinical long-term benefit for NSCLC patients.

Inclusion Criteria

  • Patients with Stage III/IV NSCLC on treatment with anti-PD-1/PD-L1 (ICI) +/- chemotherapy and a) have persistent but stable disease at least 18 weeks after starting ICI treatment, b) have radiographic progressive disease at least 18 weeks after starting ICI treatment, or c) have refractory disease defined as progressed by imaging at least 9 weeks after starting ICI treatment
  • Measurable disease including a lesion that is amenable to injection
  • Able and willing to undergo a pre-treatment and on-treatment biopsy
  • ECOG Performance status of 0 or 1
  • 18 years of age or older
  • Granulocyte count (ANC) ≥ 1,000/mm3
  • Peripheral lymphocyte count ≥ 500/mm3
  • Hemoglobin ≥ 8 g/dl (patients may be transfused to meet this criterion)
  • Platelets ≥ 75,000/mm3
  • Total bilirubin ≤ 1.5 x upper limit of normal, except for patients with known Gilbert disease who must have total bilirubin ≤ 3 x upper limit of normal
  • SGOT (AST) ≤ 5x upper limit of normal and if elevated, not clinically significant such that ICI can continue
  • INR/aPTT within normal limits or, if on anti-coagulation, it must be clinically acceptable to hold anti-coagulation for the injection procedures as appropriate
  • Serum creatinine < 2mg/dl and calculated creatinine clearance > 30ml/min
  • Clinically eligible and willing to continue ICI
  • Patients must give study specific informed consent prior to enrollment

Exclusion Criteria

  • Patients with a history of severe hypersensitivity reaction to ICI
  • Patients who require ongoing therapy with systemic immunosuppressive drugs including systemic corticosteroids (>10 mg prednisone per day or equivalent) - premedication for ICI or chemotherapy is allowed
  • Patients with a history of active autoimmune disease requiring treatment in the past 2 years
  • Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active hepatitis, or psychiatric illness/social situations that would limit compliance with study requirements
  • Women who are pregnant, lactating or intend to become pregnant during the study
  • Patients who are known to be HIV positive
  • Patients with a history of hypersensitivity or allergic reactions to valacyclovir or acyclovir
  • Patients with significant heart disease (New York Heart Association Functional Classification III or IV)
  • Patients with oxygen dependence (daily use)
  • Tumor impinging on a neurovascular structure such that inflammation in the site may put patient at risk of compromise as determined by the investigator

New York

New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Status: ACTIVE

This trial seeks to add GMCI to stage III/IV NSCLC patients who are on standard of care first

line ICI with evidence that the treatment may not be optimal but have the potential for

delayed clinical benefit such that continuing the ICI is indicated. Studies of first line ICI

have shown that most patients that will respond, respond in the first few weeks of treatment.

However, a small percentage of patients have a delayed response with ICI. GMCI has been shown

to increase the response rate to ICI in animal studies. Safety and potential efficacy of GMCI

has been seen in clinical trials in over 650 patients with cancer (lung, pancreas, brain and

ovarian). The goal of this study is to evaluate if adding GMCI can increase the percentage of

patients that respond to the continued ICI. Patients may receive whatever standard of care

therapy is indicated for their disease, such as maintenance chemotherapy, bevacizumab or

focal radiation, in addition to continuing ICI. The eligibility criterion for determining

that the ICI may not be working is based on time on ICI and response status with 3 cohorts as

follows:

Cohort 1 is for patients with stable disease at least 18 weeks after starting ICI treatment,

thus they have radiographic stable disease and clinically are stable but appear to have

disease that is not responding further.

Cohort 2 is for patients with evidence of radiographic progression at least 18 weeks after

starting ICI treatment but who are clinically stable. Examples that would fit this cohort

would be patients that have disease that decreased or was stable with initial ICI therapy,

and then is slowly progressing or a new distant lesion appears on imaging, but the patient is

otherwise clinically stable.

Cohort 3 is for patients who have new lesions or progression of existing lesions at least 9

weeks after starting ICI but who are clinically stable.

The specific ICI treatment regimen on this protocol is not specified to allow for different

standard of care options with or without chemotherapy; for example, pembrolizumab alone,

pembrolizumab plus chemotherapy, atezolizumab or atezolizumab plus chemotherapy. In addition,

it allows stage III patients after chemoradiation who may be on durvalumab as their standard

of care. For example, a stage III patient may be eligible for cohort 2 if they have

radiographic progression but are clinically stable 18 weeks after starting durvalumab or

cohort 3 if they develop a new lesion at 12 weeks after starting durvalumab.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Candel Therapeutics, Inc.

  • Primary ID LuTK02
  • Secondary IDs NCI-2020-07333
  • Clinicaltrials.gov ID NCT04495153